VCAM1 and atherosclerosis: Blocking P2Y11R has been proposed to be a potential therapeutic strategy for treating atherosclerosis, as in human primary aortic endothelial cells, NF157 reduced attachment of monocytes, expression of E-selectin and vascular cell adhesion molecule-1, production of reactive oxygen species, IL-6 and TNF-α and activation of MAPK p38 induced by oxidised low-density lipoprotein, all of which contribute to this disease [72].